cannabis technology – MJ Shareholders https://mjshareholders.com The Ultimate Marijuana Business Directory Mon, 28 Oct 2019 22:38:13 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.4 CFN Media Exclusive Q&A with GoFire CEO and Founder Peter Calfee https://mjshareholders.com/cfn-media-exclusive-qa-with-gofire-ceo-and-founder-peter-calfee/ Mon, 28 Oct 2019 22:38:13 +0000 https://www.cannabisfn.com/?p=2708776

Rachelle Gordon

October 28th, 2019

Exclusive, News


In the world of cannabis, precision dosing is crucial in order to obtain the results desired. This is especially true for medical patients. And with so much talk in the news regarding vaping, it’s more important than ever for consumers to have a safe, reliable product. Enter Gofire, a company dedicated to helping people find their perfect alternative medicine regimen. Offering a full suite of community-centered products, including a smart inhaler, a dosing app, and a QR-code enabled catalogue of 3,000 partner products, Gofire aims to eliminate the guesswork that tends to come with medical marijuana. 

CFN Media recently spoke with Gofire CEO and Founder Peter Calfee about how the business came to be, how they’re revolutionizing the way people use cannabis medicine, and what’s on deck for one of the most innovative companies in the alternative medicine space.

Peter Calfee, CEO and Founder of GoFire

CFN Media:  How was Gofire developed?

Peter Calfee:  We set out on December 18th, 2014 to solve the problems of inconsistencies within the (cannabis) marketplace. We wanted to enable a consumer to quantify their consumption. When you go out to the store and you buy a bottle of Advil, you’re buying 30 capsules and each capsule contains 250 milligrams of ibuprofen. I know that I only need one to make my headache go away, whereas my girlfriend will take three to achieve the same effect.

The first step of the process was to create a consistent dose. So I sat down with my co-founder John Woodbine, and we had this concept of creating essentially a threaded syringe where we could do physical extrusion of the product out of the nozzle of a cartridge – similar to a syringe – and extrude that oil onto a gold screen and then utilize a true convection system to send heated air over and through the product that was extruded.

It took us about four months to develop that system. We realized that the accuracy from a dosing standpoint was pretty much between 2.45 to 2.55 milligrams per dose. So we’re talking about a very, very active pharmaceutical level of accuracy.

That being said, we realized that a dose is not a dose without the chemical profile associated with that dose. The analogy I like to use is lemonade and lemon juice. Eight ounces of lemonade is not eight ounces of lemon juice. There is a formula that makes up that lemonade, right? And so when we talk about 2.5 milligrams, we really want to say 2.5 milligrams of what? And so that’s when we created the idea of a “smart cartridge.”.

There’s a little microchip on the back of our cartridge. When you drop it into the device, the device recognizes a unique ID number, calls out to the server through the smartphone app, and that server then kicks back the third-party lab test results or COA (Certificate of Analysis) associated with that specific batch of product.

This allows us to now know the chemical profile of the dose. Again, with the precise dosage and chemical profile paired together, we can actually start creating consistent, repeatable experiences and give that control back to the patient, removing the fear of taking too much and being out of control, and allowing them to see that consistent, repeatable experience that they would demand and expect with any other medicine they’re putting into their body.

As we locked down dosing and chemical profile, we realized that when we talk about enabling the prescription pad, we had to communicate in a language that a patient and physician understood. If we think about what’s on a prescription pad, we have a dose, we have a chemical profile and we have a regimen, right? I want you to take this much of this particular drug, this many times a day. And that allows for a physician to be involved in that relationship, to tailor the protocols for that patient with a goal of a successful outcome in mind, and obviously tweak that protocol based on the outcome that that patient is experiencing.

So this platform that we’ve created is made up of the metered-dose inhaler as well as the smartphone application, which allows you to track your consumption and search by ailment, which actually helps you find products available in the market that works for that ailment. For the first time you can take an inexperienced consumer stepping into the space and give them the tools to make them feel comfortable and put them back in control, probably even more control than they would see with other, mainstream market pharmaceuticals they are used to consuming.

As we expanded, we realized we needed this to work for more than just the inhalable products out there. So we expanded again to create the Gofire DoseCode, our branded QR code, which allows patients to track the use and effects of products outside of inhalables, like topicals, sublinguals and edibles. 

The system works very simply in the sense that consumers can just scan the Gofire DoseCode on a product or scan that UPC barcode of a product and then access that product’s chemical formulation within the app, indicate how much they’re taking and record their experience. We collect this anonymous post-purchase consumer use feedback. And I stress the word anonymous. The entire platform is anonymous. We do not know who these individuals are that are on the platform. Everyone is assigned a unique ID number, but we’re actually able to use that crowdsourced information, and provide that back to the consumers and patients. So again, the goal in mind being to help them find a product that will work best for them.

For example, someone who’s looking for medicine to help with their PTSD can lean on the Gofire community, search for PTSD and be provided with a list of products that has worked for others struggling with PTSD. So the patient will find a product has been rated 732 times with a 4.8 star rating for PTSD and be able to think, “Well maybe that’s a good place for me to start” versus just shooting in the dark and asking a budtender.

So the goal, again being to bring a little bit more transparency and connectivity, not just connecting a consumer to the delivery mechanism, but actually connecting that consumer with other consumers that are dealing with similar use cases. And the goal in mind being able to provide better care.

On the other side, we’re also able to take this anonymized data and pass it back to the companies that are actually making these different formulations to give them insight into how they are actually working in the market. If they’re trying to build something that’s going to help with sleep and insomnia, well how do we actually run a study? And say we’ve looked at again, 5,000 people that have consumed your product. It’s really actually not helping for sleep. We can help tailor again through batch to batch to batch help them build better products, more suited to the specific needs of the consumer and patient.

CFN:  How will the data you collect, and the device in general, change the face of medical cannabis?

PC:  I think there’s two pieces to the puzzle here. One is this system of consistency and control enables researchers to actually set up studies and run trials that can be peer reviewed because they have absolute control over the variables within each medicating session. That’s going to expedite the research that’s coming out on this plant and therefore continue to validate and expose the pros and cons of this plant so that again, physicians and patients can receive better care.

I think the other side of it is we’re actually for the first time starting to understand how these masses of products being released in the marketplace are affecting consumers. This is both on the negative and positive side. At the end of the day, we’re dealing with a very complex plant made up of hundreds of different chemical compounds. This is not a standard pharma play in the sense that we’re going to identify one to three specific chemical compounds that are going to address pain. Again, in the sense of mainstream pharmaceutical markets, we’ve got a raptness of chemical compounds here. Because of the entourage effect, we want to encourage that raptness, but we want to also understand the effects it will have.

I think, again, because of this concept of crowdsourced education among a connected community, the effect will be better care and better outcomes for patients in need. I also believe that because we’ve created this consistent, reliable means of providing a dose, we will see more mainstream adoption.

For the first time, any curious adult can actually come in and say, “Okay, I know exactly how much I need to take without being an experienced consumer. I know exactly how much I need to take to make me feel a certain way, and so that I’m no longer in pain, but I’m not bombed and I can still make it to my child’s softball game.” Now, this is really important when we look at mainstream market adoption of this industry as a whole.

The GoFire metered dose inhaler and corresponding app

CFN:  The so-called “vape crisis” is getting a lot of media attention. How do you respond?

PC:   I’ve been screaming about the concerns of vaping for five years. The biggest concern was always metal particulates and heavy metals leaching into the oil because you’ve got your heating element that’s sitting in that reservoir of oil. This was a problem that we actually talked about the night that Gofire was founded: How do we solve that problem and remove the heating element from that main reservoir, and therefore remove and mitigate the fear of any heavy metal leaching coming from the hardware itself? When we talk about that threaded syringe, that extrusion technology, if you look at our cartridge, our cartridge does not have a heating element in it.

We designed it this way because we knew that this was a considerable concern. I’m frustrated that it’s taken multiple deaths and hundreds of people getting sick for people to start listening and saying, “Wow, you’re right. This is a big concern. So how do we fix it?” 

The other big concern is these additives that are being introduced. We see vitamin E, and we see propylene glycol. Back in the day it was PEG and BG. We’ve also seen MCT oil, which is hydrogenated coconut oil.

I think part of it is that the industry as a whole has been looking for solutions and regulations have not caught up to speed. Because of that, I truly believe it falls on the business owners within the space to regulate themselves until those regulations do catch up to speed. So, one of the things that we have built into our platform to solve for this is one, we have contracts and audits that are run on our filling partners to make sure that there are no additives or excipients being introduced into the solutions with it that are being filled into our cartridges.

From day one, this has been a big piece of our puzzle and the demand that we’ve made of all of our partners. Outside of that, because we have that smart cartridge, it allows us to actually again pull up a third-party report and verify exactly what’s in the cartridge. This information is again, validated, that there’s no fraudulent oil being introduced into any of our cartridges. We have those protections in place.

I think finally, now we’re in a place where everyone is waking up and saying this is something we need to look at and this is something that we need to make sure that product is being introduced into the marketplace. Especially when we looked at these emerging markets with the uneducated consumer, that we are providing, again, safe and efficacious products to the masses.

I quote my grandmother often, but she used to always say, “If you have the tools, you have a moral obligation to leave the world a better place than you found it.” It all comes down to responsibility. This really falls on the business owners to be driving these audits, and making sure they’re providing safe products to their consumer. It’s a moral obligation. That’s the bottom line.

CFN:  How does the QR code on partner packages enter the business model?

PC:  Between the QR codes and barcodes, I want to say we have more than 3,000 products on the platform, which makes up about 400 different brands. The Gofire DoseCode is a batch-specific QR code that goes on to these different packages of different products. And that again allows consumers to scan the code and see essentially the exact makeup of what’s contained within that product.

Batch specificity is crucial. Even if a product has the same name under the same brands batch to batch to batch, we see considerable inconsistencies. So, that DoseCode is batch specific, and allows for that consumer to scan it into our app, rate the products for how well it works for their pain, sleep, anxiety, PTSD (whatever use case they’re using it for) and start tracking and logging, again, the efficacy of that product. One step lower than that from a data value perspective is the barcode.

Now what’s cool about this barcode and what’s exciting about this system is it actually gives consumers the ability to tell us what products they want to track. So if you scan any barcode of any product in the marketplace and it does not yet exist in our backend on our server side, we actually ask you as a consumer to support us and your community by taking a few photos of that product. It will prompt you again if it doesn’t recognize the barcode, it just prompts you right there in the app. It’ll say, “Take a photo of the front of the packaging. Take a photo of the nutritional facts. Take a photo of the back of the packaging.”

We have someone on the backend who is taking that information and uploading it into the database. And within about 72 hours at most, that product will then be live on the platform and you can track that product and others can track that product. Again, really putting this back in the hands of the consumer to use the tool as they see fit.

We understand that different modalities are important for even within one regimen, depending on the situation. And we wanted to make sure that we were providing a full service health suite in our Gofire Ecosystem, providing access into any modality that might be part of your dosing regimen.

The iOS app is live in the app store. The Android is coming out within the next couple of weeks. But it really allows you as a consumer to tell us which products you want to track, and give you back that control.

CFN:  What does the next 18 months hold for Gofire?

PC:  You know what I can say is we’re just getting started. We believe that the future of connected health and connected medicine will give considerable insights. Again, not just within the alternative health space. From a data perspective, understanding or having early warning signs, essentially being able to send up a red flag when a patient is over-consuming, or under consuming, or misusing a product, or I say most importantly showing the low efficacy. “It’s not working. I’m still in pain. I still can’t sleep.” This is when the patient takes the wheel and says, “I’m going to take a little bit more.” Or, “I’m going to take a little bit less.” Or “I’m going to take it every three hours, not every four hours.”

We believe that the systems we are developing will act as an early warning sign for that physician and patient relationship and will allow tweaks to that regimen be done in real time providing better care.

On the hardware side, all you can say is we’re not stopping. We realize that the product that we’ve released is really a premium product and there’s a huge demand for some of these more inexpensive products in the marketplace. We are aware of that, and have been working on something that will suit that need. Although at this time I can’t go much deeper into it. I’m sure in the next story we do we’ll be able to shed a little more light on that.

CFN:  Your IP game is some of the strongest in the space. Are your competitors nervous?

PC:  Our intellectual property is something that we pride ourselves on. At this point, we file every, call it, 60 days. The innovations that are coming out of my team knock my socks off. I’m a lucky guy to work with these brilliant minds. I think a big piece from an IP perspective is we understand that we move faster and we started earlier than many of the other companies within the space, and it gave us an advantage from an IP perspective.

I will say to any company out there that is interested in working with us and is running into blockades because of our intellectual property, reach out to us. We’re in the business of impact and that means we want to support other companies and other brands that want to provide superior technology to the current product offerings in the marketplace. So, I guess what I’m saying is we know we’ve got quite the IP portrait, but if anyone’s interested in knocking on that door and wants to play with us, we’re all about it.

CFN:  What else should our readers know about Gofire?

PC:  I’d say in general we are a small team of scrappy individuals. We work like we are four times the size of what we are. Our team is incentivized; we are in a sense employee owned. So every single one of my employees is underpaid and makes up their comp package in stock in the company options in the company.

What I love about this as the leader is we’re all incentivized together. We’re not here for a paycheck. We’re here for impact, and we’re here because we know that at some point in the near future we will see multiple liquidity events. And that is when I get paid as the CEO and founder. And that is when my employees and my team gets paid. And that is when my investors get paid. There’s a collaborative deal behind this company as a private equity investor myself, I’ve never seen to the extent that I see with our company.

My biggest thing is we’re in a unique opportunity within this business where I think the applications of what we’re developing within this space, we’re looking at this industry as our sandbox. Where we will be going is again applying some of these systems and tools to mainstream medicine. At the end of the day, connecting patients, physicians, drug manufacturers, and payers with better optics to make more informed business decisions.

If you look at the data space, the most valuable data you can collect in any industry is how a consumer interacts with the product. For some odd reason within the alternative health space that just doesn’t exist. What’s even more disturbing I would say is that when we look at the healthcare and pharmaceutical space, that data doesn’t exist.

That is why we are in an opiate epidemic. Because we would have known if we had systems like Gofire in place, we would have known within 20 days of the products being released that there was considerable cases of misuse that would lead to addiction. And we would have been able to be proactive versus reactive within the marketplace.

I think this is what the mainstream medicine market needs to come out of the 20th century and step into the future of connected health.

To learn more about cannabis innovation, sign up for our free newsletter using the form to the right.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Rachelle Gordon

About Rachelle Gordon

Rachelle Gordon is a Minneapolis-based writer. Find her online at www.rachellegordon.net.


]]>
SinglePoint and Convectium: Investing in Cannabis Packaging Speed https://mjshareholders.com/singlepoint-and-convectium-investing-in-cannabis-packaging-speed/ Mon, 09 Sep 2019 14:40:26 +0000 https://www.cannabisfn.com/?p=2665841

Ash Stringer

September 9th, 2019

App, Exclusive, News, Top Story


The negative stigmas attached to cannabis continue to fade away like a puff of smoke in the wind. Most people are now well aware of the therapeutic benefits of the cannabis plant and its cousin hemp. Investors are certainly aware of the massive industry unfolding.

Against this backdrop, cannabis operations have moved from the back alley to the boardroom and innovation is thriving. The perfect storm of booming demand for product and operational efficiency has led to a proliferation of automated technology throughout the supply chain.

For JackSam Corp. (OTCQB: JKSM), which does business under the moniker Convectium, this is the perfect environment to continue roll-out of its disruptive automated solution suite that fills, caps and packages THC and CBD concentrates 60-times faster than antiquated manual methods that still dominate the market.

Click here to see the company investor presentation

For SinglePoint, Inc. (OTCQB: SING), a diversified holding firm with portfolio companies in cannabis, hemp, digital payments and solar, taking a piece of Convectium in 2017 was an investment that keeps on giving.  In March 2017, SinglePoint made an $800,000 cash-and-stock investment for 10% of then-privately held Convectium.

Click here to see the company corporate presentation

SinglePoint still holds 6.0% of JKSM outstanding stock.

The Biggest Thing Since the Dotcom Boom

Vilified for decades, cannabis is now being trumpeted as a serious medical breakthrough.

Cannabis cannabinoids can be found in more than 1,000 products, ranging from edibles to beverages to pet products to skin creams. These cannabinoids generally consist of CBD (cannabidiol), a non-intoxicating component of cannabis and hemp, and THC (tetrahydrocannabinol), the part of cannabis responsible for the psychoactive “high” often associated with marijuana.

The world is recognizing the medical benefits (and lack of side effects) of CBD. Hemp, which became legal across the U.S. at the start of 2019 through the passage of the Farm Bill, is defined as cannabis sativa containing less than 0.3% THC. In January 2018, the World Doping Agency removed CBD from its banned substance list, further validating its efficacy and safety.

33 U.S. states have legalized cannabis for medical uses, while 10 states and Washington, D.C. allow recreational uses. Last October, Canada legalized marijuana for all adults but products have been limited. Modified legislation will open the Canadian markets to a variety of new cannabis products, including extracts. That means that about 260 million people in North America has access to cannabis in one form or another.

To that end, it’s no surprise that the industry experts at Arcview Market Research and BDS Analytics are calling for the legal cannabis market in the U.S. alone to reach $22.2 billion in 2022.

Leading the growth is concentrates, which, according to the BDS’s GreenEdge have experienced 22.1% compound annual growth across 2014-2018 to now make up one-third of the total cannabis market. A deeper dive shows the cannabis oil market segment is surging, forecast to grow at a stunning 46.9% CAGR from 2019-2025 to reach $2.16 billion.

Running Circles Around Competition

Convectium is the inventor of the world’s first cannabis oil filling system and proprietary packaging systems. This is a major advancement at a time when about 80% of all concentrate products (vapes and pods) are filled manually.  By hand, oil cartridge fills are completed at a paltry 75 per hour.  Convectium’s 710 Shark system can exceed that in less than a minute on its way to produce between 6,000-12,000 in an hour.

As the image shows, none of the limited amount of competition even comes close to the speed or diversity of the 710 Shark.  When the 710 Captain and 710 Seal are added to the assembly line, the processes of “rack, fill, cap and pack” that all concentrates go through are completed by Convectium products with dramatically improve speed, while reducing waste by as much as 42%.

“Where else can one person do 6,000 cartridges, including filling and putting into blister packs, in one hour?  The answer is ‘nowhere’,” commented SinglePoint CEO Greg Lambrecht in a phone conversation with CFN Media.  “We were confident in the investment in Convectium 2-1/2 years ago and are greatly looking forward to the coming years under their new business model,” he added.

Lambrecht was referring to Convectium recently switching from a “closed system” to an “open source” business model. This is a savvy move by Convectium to make its vape, pod and cartridge trays and equipment compatible with components produced by the majority of leading global manufacturers. For the first time, cannabis brands and co-packers can add the 710 line to existing filling operations, greatly improving efficiency and the bottom line.

Built in the U.S.A. with UL certification, Convectium is prepping for extracts becoming legal in Canada early in 2020 by making the machines CUL certified as well.

Charged with spearheading a sales push under the new strategy, cannabis industry veteran David Hall was brought on as Executive VP of Sales at Convectium.

Strength in Numbers

With over 100 customers using Convectium products, the brand has built a market presence.  As the industry gets ready to experience exponential growth, Convectium leadership is taking a more aggressive approach at an opportune time. Late in July, the company penned a distribution agreement with MainStem, a leading marketplace for ancillary cannabis products and centralized purchasing. Mainstem’s online platform offers over 10,000 products and cutting-edge e-procurement functionality as it re-shapes the industry standard for how business-to-business purchasing is done in the cannabis industry.

Click here to see the company investor presentation

Further, SinglePoint is much more than just a leading shareholder in Convectium.  SinglePoint’s family of companies all have synergies with each other. To that end, SinglePoint is building its own footprint in the private label market and will use Convectium products for its clients, as well as making referrals to drive more business to Convectium. It also owns SingleSeed, an e-commerce portal selling hemp-derived CBD products.

Click here to see the company corporate presentation

“[We] recently received sample vape pens from the company and have already received lots of interest, and an order” commented SinglePoint President Wil Ralston, succinctly adding, “The cutting-edge technology allows us to provide superior products to clients.”

A Prescient Decision

A couple years ago, Wall Street was bearish on legal cannabis, shaken by uncertainty about where the market was heading against the backdrop of prohibition at the federal level. SinglePoint got ahead of the curve, seeing Convectium’s vision for automation as the future of industry. Turns out they were both right, seizing the opportunity as technology now has spread throughout the entire cannabis value chain from growing to distribution. Still, no one does it as fast or as efficiently as Convectium.

Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

Avatar

About Ash Stringer


]]>
CFN Media Exclusive Q&A with KlickTrack COO, Co-Founder https://mjshareholders.com/cfn-media-exclusive-qa-with-klicktrack-coo-co-founder/ Fri, 01 Mar 2019 20:57:26 +0000 https://www.cannabisfn.com/?p=2286802

Rachelle Gordon

March 1st, 2019

Exclusive, News


While the cannabis industry may still be in its infancy, the retail marketplace is already experiencing a revolution unlike anything we have ever seen. The need for seamless compliance, efficient sales tracking, and intuitive customer loyalty is at an all-time high and there’s only one platform available that creates one fully-integrated ecosystem for the entire vertical. KlickTrack was invented by and for the dispensary owner but is far more than a POS, featuring fully customizable solutions for day-to-day operations and beyond.

CFN Media sat down with KlickTrack Co-founder Brendan Hill and COO Craig Olson at the recent CannaCon Expo in Seattle to learn more about what sets the platform apart and the future of cannabis retail.  

CFN Media:  How was KlickTrack initially developed?

Brendan Hill: As Cannabis retail operators, my partner Steve Kessler and I learned a lot. One of the major flaws we found revolved around the systems that support us. The track and trace systems, the point of sale systems, the menu systems, the texting systems, the loyalty programs – they were all sort of a patchwork of different companies that were available to us, but they’re all pretty expensive and none of them talk to each other.

Steve Kessler and Brendan Hill of KlickTrack, at the 2019 CannaCon Seattle.

So, we said to ourselves, “Why don’t we just do it ourselves and create something which solves all of our pain issues, brings everything together and has all of our metrics in one place?”

We partnered up with world-class developers who come from a background of amazing products that they had brought to market. We told them where our pain points were and they said, “No problem, let’s get to it.” They already had a compliance translator from their processor tool that they’ve been developing, which was then used for KlickTrack.

Along with the team, we worked out all the issues, found out what our pain points were and what we have now is a product which, I think far exceeds our competitors. It actually brings together the patchwork of services that I was talking about before. So now you have menu, you’ve got texting, you’ve got data analysis. We’ve got the ability for a customer to come into the shop, pull up on their phone basically a picture menu and be able to order right from there. That order goes into our back office, gets fulfilled, and pops up for the customer, speeding up the entire retail process.

CFN:  KlickTrack allows producers to get up close and personal with the consumers. Tell us how?

BH:  All cultivators and processors want to have their product presented at its best. They don’t want to be just on a paper menu with their name; they want to be seen and to entice. We wanted a customer to come into the shop, be able to see beautiful pictures and descriptions of different strains and say, ‘Oh, that one looks good’.

Producers can update brand photos and add videos to our platform in order to interact with potential customers. Perhaps they’ll see a sale sign displayed for say Lazy Bee Farms or Canna Oraginix they’ll click on that or they’ll walk by a case that has Lazy Bee in it and it will pop up on their KlickTrack menu, they’ll see a picture of it and then click on it. They’ll get the testing results and then, they click even further, they’ll see where Lazy Bee is grown and they’ll see their practices.

Our platform is going to grow quickly just like the industry, and we want to help to elevate the entire industry. I think processors, retailers, everyone should be talking the same language and I think KlickTrack is that language – we are bringing the industry together.

CFN:  Technical difficulties have plagued cannabis tracking and POS software in the past. How does KlickTrack solve these problems?

BH:  We’re retailers ourselves and we know the frustration of having an outage. We know the headache of having your sales system go down as ours did on 4/20 in 2018 – one of the busiest days in the industry all year. It went out for like five hours. We were writing paper tickets to be compliant and there were lines backing up, and we were just so frustrated and that was one of the reasons why we said to ourselves “We have got to create our own POS.”

What’s great about KlickTrack is that it’s cloud-based, our scanners super fast, it works on all iOS devices and available now at the App Store. You could literally be in the middle of a field at a concert or a festival and you could basically run KlickTrack anywhere. From home, you can type in an order and just send the order to the store. It’ll be filled and sent right out either for in store pickup or in states that allow it, for delivery

CFN:  What makes the perfect strategic partner for KlickTrack?

Craig Olson:  We’re seeking partners that can help us not only financially but also with our business strategy. We’ve begun discussions with larger funds and entities already and are actively planning our raises. We seek not only great investors but experts in this specific market.

We’ve been lucky enough to find some entities and individuals that meet that criteria. As opposed to companies that are being opportunistic that may have a point of sales that covers other, vastly different industries. this is a product built by experts in the industry who knew exactly what problems exist, and why they exist. I think that’s the primary competitive advantage and also the platform upon which it was built is new as opposed to PC-based solutions from two decades ago.

CFN:  What is your personal connection to cannabis?

BH: First and foremost I’m a musician; I’m the drummer for the band Blues Traveler, and still tour today. For me, as a musician and for many artists, what cannabis does it kind of gets you into that flow state, so that you’re able to create without thinking too much about all your other issues going on, Using cannabis helps me to stay focused and get into the zone. I personally use cannabis for more recreational purposes, but I see every day the benefits it has medically.

We have a lot of medical patients coming into our store, and they’re going through such difficult times where cannabis is the only thing that’s really helped them. It feels wonderful to be able to be able to help people like that with a product they can grow in their backyard, a product that can possibly help them to avoid opioids for pain management. I think we’re seeing that cannabis is making major breakthroughs in a lot of areas.

CFN:  How can people within the industry help guarantee it thrives during such uncertain times politically?

BH:  There is enormous potential for brands to go from small, medical-only statewide producers to nationwide fame. All that takes is to make sure they go through the licensing process properly. I think a lot of medical growers shun the compliance thing because they don’t want to deal with it.

I think in order for us to all come together and elevate the whole industry, we need all those great growers in the medical industry to come in and just get their names out there. I encourage everybody to go through the licensing process because the more companies that come online, the bigger the lobby, the bigger voice we have in Washington, and the more tax money that we pay. Think of the roads we could build, think of the education we could fund. Think of all that. Get into the legal industry because you can make change.

To learn more about cannabis technology, sign up for our free newsletter using the form on the right.

Rachelle Gordon

About Rachelle Gordon

Rachelle Gordon is a Minneapolis-based writer. Find her online at www.rachellegordon.net.


]]>